Women may be less likely to go back to work after severe stroke

Translate to Spanish or other 102 languages!

More than one-third of people who have a clot removed from a major blood vessel in the brain after a stroke return to work within three months, according to a new study from Germany. But women were half as likely to do so as men. Image for illustration purposes
More than one-third of people who have a clot removed from a major blood vessel in the brain after a stroke return to work within three months, according to a new study from Germany. But women were half as likely to do so as men. Image for illustration purposes

Mega Doctor News

- Advertisement -

By American Heart Association News

More than one-third of people who have a clot removed from a major blood vessel in the brain after a stroke return to work within three months, according to a new study from Germany. But women were half as likely to do so as men.

The study, published Thursday in the American Heart Association journal Stroke, found women and men were more likely to return to work if they were treated with a combination of mechanical blood clot removal and clot-busting medication to clear their clogged blood vessels than if they just had their clots removed.

- Advertisement -

“Returning to work after a severe stroke is a sign of successful rehabilitation,” lead study author Dr. Marianne Hahn said in a news release. She is a clinician scientist in the department of neurology at Johannes Gutenberg University in Mainz, Germany. “Resuming pre-stroke levels of daily living and activities is highly associated with a better quality of life.”

When blood clots in the brain block a major artery, they can cause a severe stroke with the potential for serious disability, making it less likely people will return to work. Clot-caused ischemic strokes account for 87% of all strokes in the U.S. Blockages in large vessels account for 24%-46% of ischemic strokes. Stroke is the fifth-leading cause of death in the U.S. and a leading cause of disability.

Endovascular mechanical thrombectomy is a procedure that uses a slim catheter to remove a clot blocking a large blood vessel in the brain. This procedure, along with clot-busting medications, is considered standard practice for the treatment of some severe strokes.

Researchers analyzed data for 606 men and women, ages 18 to 64, in Germany who survived large vessel occlusion ischemic strokes between 2015 and 2019. Participants, all of whom worked prior to their strokes, were treated with a mechanical thrombectomy. A subset of 370 patients also received clot-busting medications. They compared those who went back to work 90 days after having a thrombectomy to those who did not return to work.

- Advertisement -

“Women in our cohort were younger at the time of their stroke, were more likely to be non-smokers and were more likely to have no residing significant disability when discharged from the hospital compared to the men in our study,” Hahn said. “Despite having more of these favorable characteristics for return to work, we did not observe a higher re-employment rate in women before considering these differences.”

That means there is something else behind the reasons for not returning to work, she said.

What could help, Hahn said, are “targeted vocational and workplace rehabilitation interventions (that) have been shown to improve rates of return to work. And previous studies have also found that returning to work is associated with increased well-being, self-esteem and life satisfaction.”

Women and men treated with both thrombectomy and clot-busting medications were nearly twice as likely to return to work as those who just had a thrombectomy.

The study did not include information on the types of jobs people returned to, whether they worked full or part time, or whether they resumed the same positions after their strokes. Nor were social determinants of health accounted for in this research.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Robotic Surgery Program Expanded at STHS McAllen

From smaller incisions and less pain to shorter hospital stays and faster recovery times, robotic-assisted surgery is changing the way patients experience surgical care.

Texas Oncology to Host Breast Cancer Awareness Symposium in McAllen. FULL TO CAPACITY. NO MORE ROOM.

The Breast Cancer Awareness Symposium 2026 is an educational and networking event hosted by Texas Oncology and sponsored by Caris Life Sciences, bringing together oncology specialists, surgeons, advanced practice providers, and community healthcare professionals to discuss the latest advances in breast cancer prevention, diagnosis, treatment, survivorship, and reconstruction. The symposium's theme, "Breast Cancer 2026: Early Detection, Modern Care, and Survivorship Through Community Partnership," highlights the importance of multidisciplinary collaboration and patient-centered care

Highway Crash Leads to Unexpected STC Connection

What began as a flat tire on the side of a highway turned into a frightening collision and an unexpected encounter for South Texas College faculty member Jesus Amaya, when the paramedic who responded to the scene turned out to be one of STC’s graduates.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -